Lv12
78 积分 2024-09-30 加入
Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study
15天前
已完结
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
1个月前
已完结
Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH)
1个月前
已完结
体部立体定向放疗在肝细胞癌中的应用进展
1个月前
已完结
体部立体定向放疗在肝细胞癌中的应用进展
1个月前
已关闭
Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy
1个月前
已完结
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
1个月前
已完结
Host Determinants of Immune Checkpoint Inhibitor Efficacy: Immune, Genetic, Metabolic, and Lifestyle Factors
4个月前
已完结
皖公网安备34019202002308
